Dalbavancin / Oritavancin / Telavancin

Does Dalbavancin / Oritavancin / Telavancin work?

Yes, in large controlled trials; one covered 1,312 patients.

Each drug was approved on randomized double-blind non-inferiority trials against vancomycin-based standard therapy. The trial in the citations, the pooled DISCOVER 1 and 2 programme for dalbavancin, randomized 1,312 patients and found early clinical response in 79.7% with dalbavancin against 79.8% with vancomycin followed by linezolid. ¹²

Boucher and colleagues reported DISCOVER 1 and 2. These were two identically designed double-blind, double-dummy randomized trials. They ran at 140 sites in 2011 and 2012. Patients with acute bacterial skin infections got dalbavancin on days 1 and 8. Others got vancomycin by vein for at least three days. They could then switch to oral linezolid. Treatment ran 10 to 14 days. Early response meant two things at 48 to 72 hours. The fever was gone, and the lesion had stopped spreading. It occurred in 525 of 659 dalbavancin patients (79.7%). It occurred in 521 of 653 comparison patients (79.8%). That met the non-inferiority goal. Fewer adverse events were reported with dalbavancin. ¹

The oritavancin and telavancin labels summarize their own non-inferiority programs against vancomycin. These were SOLO I and II for oritavancin. For telavancin they were ATLAS in skin infection and ATTAIN in pneumonia. Telavancin's pneumonia approval was limited to patients with no suitable alternative. The reason is that deaths were higher in a subgroup with pre-existing kidney impairment. ³⁴

Read the full Dalbavancin / Oritavancin / Telavancin page

Reference information only, not medical advice. Drawn from the Dalbavancin / Oritavancin / Telavancin article, fact-checked against the cited sources. No dosing anywhere on this site.